Health Condition 1: L99- Other disorders of skin and subcutaneous tissue in diseases classified elsewhere
Conditions
Interventions
Intervention1: Topical Luliconazole: Topical Luliconazole in patients of Tinea Cruris and or Tinea Corporis, Total duration of the study is one and half years
Control Intervention1: Topical Naftifine:
Sponsors
Rupam Roy
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients presenting with clinical signs and symptoms consistent with Tinea Cruris and or Tinea Corporis 2.Laboratory confirmation of dermatophyte infection by positive potassium hydroxide microscopy
Exclusion criteria
Exclusion criteria: 1.Pregnant or breastfeeding women 2.Individuals who are immunocompromised or have uncontrolled diabetes mellitus 3.Participation in another investigational drug or clinical trial within the past 30 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical response in the form of clinical and mycological cure by changes in erythema , scaling , pruritis in tinea corporis and /or tinea cruris after 28 days of treatment and at the end of 42 days in both groupsTimepoint: Clinical response in the form of clinical and mycological cure by changes in erythema , scaling , pruritis in tinea corporis and /or tinea cruris after 28 days of treatment and at the end of 42 days in both groups | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse EventsTimepoint: 4 weeks & 6 weeks | — |
Countries
India
Contacts
Public ContactDebasis Ray
Agartala Government Medical College and GBP Hospital
Outcome results
None listed